ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,212.20
0.10%
S&P ASX All Technology
3,444.90
0.35%
Brent Oil
70.83
-0.17%
US Dollar vs AUD
1.44443
-0.45%
Bitcoin
65,721.96
0.83%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Taiwan Liposome Company Ltd (TLC) Share Price

Taiwan Liposome Company Ltd

Taiwan Liposome Company Ltd (TLC)

Lottery Corporation Ltd
7.00
0.00
( 0.00% )
Updated: 10:00:00
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
7.00
Bid
6.66
Offer
7.10
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
7.00
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

Ask ADVFN Intelligence (AI)

TLC Latest News

More News

Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Breaking Abstracts Session

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed...

20 November 2023
GlobeNewswire Inc.

TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to...

08 November 2023
GlobeNewswire Inc.

TLC Announces TLC599 Agreement with Endo

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...

13 June 2022
GlobeNewswire Inc.

TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 07, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...

07 March 2022
GlobeNewswire Inc.

TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares

This communication does not constitute an offer of any securities for sale or subscription or a solicitation of an offer to purchase or subscribe to any securities in any jurisdiction. The...

08 September 2021
GlobeNewswire Inc.

TLC Reports Second Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 12, 2021 (GLOBE NEWSWIRE) -- TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet...

12 August 2021
GlobeNewswire Inc.

TLC Announces Details of Stock Swap Transactions

TAIPEI, Taiwan, July 05, 2021 (GLOBE NEWSWIRE) -- Taiwan Liposome Company (Nasdaq: TLC, TWO: 4152, “the company”), a clinical-stage specialty pharmaceutical company developing novel...

05 July 2021
GlobeNewswire Inc.

TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 26, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...

26 May 2021
GlobeNewswire Inc.

TLC Announces Approval of New Drug Application of Liposomal Amphotericin B in India

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 25, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...

25 May 2021
GlobeNewswire Inc.

InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 – Inhalable Liposome Formulations of Antiviral Drugs for COVID-1...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 23, 2021 (GLOBE NEWSWIRE) -- InspirMed Inc., a subsidiary of TLC (Nasdaq: TLC, TWO: 4152) that specializes in the development of proprietary...

23 May 2021
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CNEYCN Energy Group Inc
US$ 1.16
(100.03%)
82.83M
ONCOOnconetix Inc
US$ 5.97
(77.92%)
19.84M
CNETZW Data Action Technologies Inc
US$ 0.975949
(52.49%)
2.28M
XPONExpion360 Inc
US$ 0.084
(30.43%)
106.52M
DUOFangDD Network Group Ltd
US$ 1.3648
(27.55%)
42.28M
SEELSeelos Therapeutics Inc
US$ 3.8276
(-23.45%)
339.95k
NVNOenVVeno Medical Corporation
US$ 3.5155
(-21.88%)
418.7k
ACHCAcadia Healthcare Company Inc
US$ 59.41
(-21.48%)
808.74k
AYTUAYTU BioPharma Inc
US$ 2.425
(-14.88%)
31.43k
XFINExcelFin Acquisition Corporation
US$ 9.82
(-14.31%)
9.01k
XPONExpion360 Inc
US$ 0.084
(30.43%)
106.72M
CNEYCN Energy Group Inc
US$ 1.14
(96.59%)
83.42M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.165
(20.79%)
43.62M
DUOFangDD Network Group Ltd
US$ 1.369
(27.94%)
42.31M
NVDANVIDIA Corporation
US$ 122.9366
(-0.89%)
27.1M

TLC Discussion

View Posts
TraderStig TraderStig 3 years ago
#DDAmanda Chart on: $TLC

You can scan for these before they run.



#DDAmanda Promo Code: dsh888

What the Fact (Factor) Column is:

The Factor is a proprietary indicator used for scanning in #DDAmanda.

It's defined as Today's $Traded divided by the average daily $Traded (20 day avg).

SO, if a stock has say a 10 Factor that day, it means she traded 10 Times the $ she normally trades.

That's significant, and many times indicates that a run in the stock is coming.




👍️0
FROZENFLAME FROZENFLAME 4 years ago
$TLC READY FOR SOME NEWS .
👍️0
FROZENFLAME FROZENFLAME 4 years ago
$$$TLC$$$
👍️0
FROZENFLAME FROZENFLAME 4 years ago
https://ir.tlcbio.com/news-releases/news-release-details/tlc-announces-acceptance-manuscript-anti-covid-19-program
👍️0
FROZENFLAME FROZENFLAME 4 years ago
Nice close .
👍️0
FROZENFLAME FROZENFLAME 4 years ago
Hit me with the NEWS !!
👍️0
FROZENFLAME FROZENFLAME 4 years ago
4 weeks almost over, hydroxychloroquine. Study medication is administered through inhalation via a commercially available portable vibrating mesh nebulizer, and all subjects will be followed up for 4 weeks.
👍️0
FROZENFLAME FROZENFLAME 4 years ago
Adding .
👍️0
FROZENFLAME FROZENFLAME 4 years ago
This my baby, I’m adding more tomorrow .
👍️0
FROZENFLAME FROZENFLAME 4 years ago
https://ir.tlcbio.com/news-releases/news-release-details/tlc-announces-appointment-thomas-h-bliss-jr-mba-chief-business
👍️0
FROZENFLAME FROZENFLAME 4 years ago
Adding some more, updates coming soon .
👍️0
FROZENFLAME FROZENFLAME 4 years ago
O/S 5M one more update $10s will be up with no time .
👍️0
FROZENFLAME FROZENFLAME 4 years ago
https://finance.yahoo.com/news/tlc-enrolls-first-subject-phase-084100428.html
👍️0
FROZENFLAME FROZENFLAME 4 years ago
4K shares at $9.00 after hours !!!!
👍️0
FROZENFLAME FROZENFLAME 4 years ago
Huge potential !!!
👍️0
FROZENFLAME FROZENFLAME 4 years ago
Nice close .
👍️0
FROZENFLAME FROZENFLAME 4 years ago
I’m in $$$TLC$$$
👍️0
crudeoil24 crudeoil24 4 years ago

TLC Receives Australian and Taiwan Approval to Initiate Phase I Clinical Trial of TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19
👍️0
otcmoneydoubler otcmoneydoubler 4 years ago
TLC MOVING ON COVID AUSTRALIAN NEWS
👍️0

Your Recent History

NASDAQ
TLC
Taiwan Liposome
USOTC
FTDL
FirsTime Design (CE)
BIT
P1ORK5
BNP Paribas Issuance
NASDAQ
APGE
Apogee Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved